Further work is required to clarify the roles of other major protagonists, particularly looking at the nuanced role of oestrogen in different tumour types, thinking laterally about how to measure the true effects of IGF-1 in obesity and measuring markers of insulin signalling over time in human obesogenic tumour sites. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.